ProCE Banner Activity

EV-103: Phase I/II Trial of Enfortumab Vedotin Plus Pembrolizumab in Patients With Locally Advanced/Metastatic Urothelial Carcinoma

Slideset Download
Conference Coverage
Combination enfortumab vedotin plus pembrolizumab demonstrated rapid, durable response, regardless of PD-L1 status, in untreated, cisplatin-ineligible patients with advanced urothelial carcinoma.

Released: June 05, 2020

Expiration: June 04, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono